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Abstract:
Migraine is a frequently disabling disorder which may require inpatient treatment. Admission
criteria for migraine include intractable migraine, nausea and/or vomiting, severe disability and
dependence on opioids or barbiturates. The inpatient treatment of migraine is based on
observational studies and expert opinion rather than placebo-controlled trials. Well-established
inpatient treatments for migraine include dihydroergotamine, neuroleptics/antiemetics, lidocaine,
intravenous aspirin and non-pharmacologic treatment such as cognitive-behavioral therapy.
Short-acting treatments possibly associated with medication-overuse, such as triptans, opioids or
barbiturate-containing compounds, are generally avoided. While the majority of persons with
migraine are admitted on an emergency basis for only a few days, outcome studies and infusion
protocols during elective admissions at tertiary headache centers suggest a longer length-of-stay
may be needed for persons with intractable migraine.
Keywords:
Migraine, inpatient, chronic migraine, migraine pharmacology, hospitalization, chronic daily
headache.
Introduction:
Migraine is a highly prevalent headache disease which typically affects patients during their
most productive years. In the Global Burden of Disease Survey 2010, it was ranked as the third
most prevalent disorder and seventh-highest specific cause of disability worldwide [1]. In the US
population over 11 million persons suffer from migraine headache with moderate to severe
disability [2]. From 1980 through 1989, the prevalence of chronic migraine headaches in the
United States increased nearly 60%, from 25.8 per 1000 persons to 41.0 per 1000 persons [3].

Although the vast majority of patients with migraine receive outpatient treatment alone, inpatient
migraine treatment accounts for a substantial percentage of the overall cost of the disorder. In
2008 over 50 thousand patients were hospitalized for migraine in the US, representing 63% of all
admissions for headache with a cost of $375 million, roughly $7500 per patient [4]. Lucado et al.
reviewed emergency department (ED) visits and inpatient admissions for headache in the US
using data from the Healthcare Cost and Utilization Project. Over 3 million persons visited the
ED for headache in 2008, with migraine the most common diagnosis. Migraine was also the
most common diagnosis leading to admission. The average length of stay of patients with a
primary diagnosis of headache was 2.7 days, less than the average for all admissions, 4.6 days
[5].
Inadequately treated migraine can lead to frequent ED visits, unneeded diagnostic testing, and
severe economic burden due to loss of functioning [6]. Missing or impaired function at work
accounts for most of the economic impact of migraine [7]. A small minority of persons with
migraine account for the majority of missed work days [8]. A retrospective review showed that
migraineurs generated nearly twice as many medical claims as comparison group patients with
higher use of emergency services. Total medical and pharmacy claims costs were $3.4 million
for the migraine group compared to $2.1 million for the comparison group. Diagnostic
procedures in persons with migraine generated a yearly cost of $83,537 compared to $13,140 in
the comparison group [9]. Using a cost-responsiveness analysis, chronic headache sufferers cost
187% more than patients who do not suffer from headache, surpassing other major chronic
conditions such as diabetes and heart disease with a 176% and 136% cost increment respectively
[10].

Overuse of acute medications frequently complicates migraine treatment. Opioids and
barbiturates are particularly linked to migraine progression [11]. Headache sufferers are more
likely to worsen from overusing abortive medications when compared to other patients with
chronic pain [12]. Discontinuation of these medications is imperative for improvement but may
produce profound acute withdrawal, including the risk of seizure from barbiturate
discontinuation, making outpatient treatment very difficult [13]. Besides the obvious goals of
reducing suffering and improving function, effective inpatient treatment for migraine can
eliminate medication overuse [14]. Patients overusing acute medications such as opioids,
caffeine or barbiturate-containing compounders have greater psychiatric comorbidity such as
major depressive disorder, panic or anxiety disorders [15]. Inpatient treatment can be necessary
for patients dependent on these medications with progressive or intractable migraine.
Initial Evaluation and Admission Criteria:
Most patients with migraine are successfully treated as an outpatient by using appropriate acute
and preventive medications, lifestyle changes, psychological therapy and interventional
procedures such as behavioral therapies, dietary restrictions, health enhancement activities,
interventional treatments such as neurotoxin treatments, trigger point injections, nerve blocks
and devices [16].
An increasing number of outpatient infusion centers and comprehensive outpatient treatment
programs have emerged, providing an even broader dimension of outpatient level care. [17-19] .
As with most disorders it is essential to matching the intensity of service to severity of illness.
Diener and colleagues summarized the experience of several integrated care settings in Europe

and USA and concluded that integrated multidisciplinary headache care improves outcomes and
decrease costs with fewer unnecessary diagnostic testing and emergency department visits [20].
Many of these patients require a more intense and controlled environment of care during
treatment than cannot be safely provided in an outpatient setting. Factors that determine the
optimal setting, methods, and results of such treatment have come under increasing scrutiny
secondary to the cost of in-patient care [21] Several expert surveys have attempted to define the
conditions requiring inpatient hospitalization. A recent survey distributed among American
Headache Society members showed that nausea and vomiting were the most popular factor
favoring inpatient admission (63.4%) followed by medication overuse headache with opioids
(61.3%) or barbiturates (58.1%). Interestingly, the majority of participants did not consider
overuse of triptans and NSAIDs alone to warrant admission [22]. Freitag et al [21] reviewed
and summarized admission criteria for migraine and other headache. Based on multiple expert
criteria [23,24] the most important indications requiring inpatient hospitalization for migraine
are as follows:


Status migranosus



Dehydration or intractable nausea and/or vomiting



Dependence on opioids, barbituates requiring detoxification



Treatment or medical disease requiring careful observation



Failed outpatient treatment or frequent ED visits requiring inpatient pain or psychiatric
management

Villareal performed a comparative study between 212 out patients and 222 inpatients and
analyzed variables such as anxiety, depression, self-rating pain, analgesic medication use and

length of headache history as potential risk factors for hospitalization. The conclusion was that
inpatients scored significantly higher on anxiety and depression scale, rated higher pain scales
and used more analgesics than the outpatient counterparts. Identifying risk factors to guide health
care providers to assign patients to an inpatient status in advance can reduce futile treatment and
its costs [25].
The inpatient treatment of migraine typically involves admission through an emergency
department. For patients with long-standing intractable migraine, however, a longer length of
stay may be required to successfully treat the disorder. Studies reviewing hospitalization at
specialized headache centers report longer lengths of stay with a median of up 13 days.
Treatment of long-standing migraine in the inpatient setting improves pain, alleviates disability
and reduces analgesic use, with long-term benefit [26,27]. In fact patients with medicationoveruse, specifically triptans, often improve the most [26]. Although most patients will continue
to experience headache or migraine a small number, approximately 10%, may remain headache
free [27,28] The majority of specialized centers utilize both medications and psychological
services to treat migraine in the inpatient setting.
Inpatient migraine treatment in adults:
Multiple options for inpatient treatment of migraine exist, though the literature is largely
uncontrolled and observational. Among the most utilized are intravenous medications including
dihydroergotamine, neuroleptics, diphenhydramine, non-steroidal anti-inflammatory drugs
(NSAIDs), anticonvulsants and magnesium. In addition to facilitating infusion treatments of
migraine, inpatient care allows for withdrawal of overused medications such as opioids or
barbiturates with close monitoring and treatment of withdrawal symptoms [26]. Comprehensive

headache care centers use a multi-disciplinary approach combining pharmacologic treatment
with behavioral therapies such as biofeedback, psychotherapy, or relaxation techniques,
sometimes continued after discharge [6,27,28].

Pharmacologic treatment:
1.

Dihydroergotamine (DHE). Repetitive dosing of DHE to treat refractory migraine was

first described by Raskin [29]. Fifty-five patients with continuous headache for at least two
months, most with medication overuse, were treated with between 0.3mg and 1mg of intravenous
DHE every 8 hours for 2 days. Forty-nine patients (89%) were headache-free within 48 hours,
with most reporting lasting benefit at follow-up.
Long term prognosis following in patient treatment with IV DHE has also been evaluated.
Silberstein and colleagues retrospectively studied the 2 year outcome of 50 patients suffering
from chronic daily headache (CDH) associated with the overuse of analgesics admitted to their
inpatient headache center. All 50 patients had some sort of chronic daily headache including
chronic or transformed migraine (37), new daily persistent headache (NDPH) (12) and chronic
tension-type headache (1). All patients suffered from overuse of either or combination of
analgesics (narcotic and non-narcotic), caffeine, butalbital and ergotamine. At 3 months follow
up, 44% of patients had an excellent or good result (excellent defined by >90% reduction in
either headache intensity or frequency or > 75% reduction in both; good defined by >75%
reduction in either headache intensity or frequency or > 50% reduction in both). At 6 months
follow up 56% had a good or excellent result. At 24 months (2 years follow up) 59% of patients

remained showing an excellent or good result. The authors concluded that most patients (87%)
continued to show significant improvement after 2 years of hospital admission [30].
Other chart review studies confirm long-term benefit after inpatient DHE treatment [31].
Nagy reported 114 patients with chronic migraine treated with a total dose of between 8.25mg
and 11.25mg of intravenous DHE, 84 (74%) reported at least some subjective benefit, 76 (67%)
reported headache freedom during treatment, and 85 (75%) reported headache freedom within
one month following treatment [32]. Both headache frequency and severity were reduced and
the effect lasted an average of 28 days. Higher total DHE dose and less nausea were significant
predictors of headache freedom.
Jauslin and Goadsby [33] evaluated 47 patients with migraine hospitalized for the management
of severe headache. Of the 47 patients, 17 had status migrainosus and 12 had chronic daily
headaches qualitatively of a migraine type. Treatment in all comprised cessation of all previous
acute medication, plus one of the following: intravenous dihydroergotamine (DHE) 0.5mg eight
hourly (7 patients), intravenous injection of lidocaine (lignocaine) with a bolus of 1 mg/Kg being
followed by an infusion of 2mg/minute for two days (11 patients), combination of these two
techniques (18 patients) and subcutaneous injection of sumatriptan 3mg, repeated in 30 minutes
if necessary (8 patients). Of 12 patients treated with i.v. DHE, lidocaine infusion or both, 8 were
headache-free within 2 days, 2 improved and 2 were unchanged. In contrast 5 of the 6 patients
treated with sumatriptan were headache-free within 2 hours.
Relja and colleagues evaluated 101 patients who met ICHD 2 criteria for MOH and attempted to
identify predictors of treatment efficacy. The time elapsed from the beginning of the
detoxification to the resolution of headache (referred as TCDHR) was also evaluated as a way of

measuring efficacy of the therapeutic protocol. The results confirmed that migraine without aura
was the most common primary headache associated with medication overuse (75 of 101
patients). The use of IV DHE co administered with metoclopramide proved to be safe and
effective and at 3 months follow up no patient relapsed to overusing medication. Patients
overusing triptans had a faster resolution of their headaches. The mean length of hospital stay in
this study was 10 days [34].
2.

Lysine acetylsalicylate (aspirin). A few studies have shown intravenous aspirin to be an

effective treatment for acute migraine attacks [35,36]but only one has examined its use in an
inpatient setting, given primarily for medication withdrawal headache [37]. In this retrospective
review of 91 patients with migraine, one gram of intravenous aspirin had a moderate effect in
62% and good effect in 27%. Intravenous aspirin was well-tolerated, with only minor adverse
events reported. Of note, of 21 patients with a history of upper gastrointestinal problems or
NSAID intolerance, only 3 (14%) reported nausea or abdominal pain with intravenous aspirin.
3.

Valproate. One uncontrolled study showed that eight (80%) of ten patients with chronic

migraine treated with a loading dose of 15 mg/Kg followed by 5 mg/Kg every 8 hours of
intravenous valproate every eight hours had improvement of the pain. 57% was pain free [38].
Intravenous valproate may also be effective for acute migraine in the emergency department and
outpatient settings [39-41].
4.

Lidocaine. Two retrospective reviews have examined the use of intravenous lidocaine for

chronic migraine. Of 71 patients with chronic daily headache (90% with migraine) and
medication overuse treated with lidocaine infusion at 2mg/min for seven to ten days, 90% noted
improvement in headache by discharge, with 60% achieving headache freedom [42]. Six months

later, headache was absent in 51% and improved in an additional 20%. Of 68 patients with
chronic daily headache (60% with migraine) treated with between 1mg/min to 4mg/min of
lidocaine for a mean of 8.5 days, 57% had some improvement and 25% achieved headache
freedom [43]. Most patients had received intravenous DHE, neuroleptics or corticosteroids
during the hospitalization prior to lidocaine.
Side effects were generally mild, including nausea, hypotension, and arrhythmia, and did not
lead to treatment discontinuation. However, hallucinations [44] and other psychiatric side effects
are not uncommon [45].
5.

Magnesium. The data available regarding the use of intravenous magnesium for the

treatment of headache in adults is conflicting, most reports focusing on its use in the emergency
setting rather than in patient and for the treatment of migraine headaches. Bigal et al. assessed
the effect of 1 g intravenous magnesium sulphate on the pain and associated symptoms (nausea,
photophobia and phonophobia) in patients with migraine without aura and migraine with aura
compared to placebo. In the migraine without aura group there was no statistically significant
difference in the patients who received magnesium sulphate vs. placebo in pain relief. In the
migraine with aura group though patients receiving magnesium sulphate presented a statistically
significant improvement of pain and of all associated symptoms compared with controls. Data
supports use of magnesium sulphate for the treatment of all symptoms in migraine with aura, or
as an adjuvant therapy for associated symptoms in patients with migraine without aura [46].
In a randomized, single-blind, placebo-controlled trial 15 patients received 1 g intravenous
magnesium sulfate given and were compared to 15 patients who received 10 mL of 0.9% saline

intravenously. Magnesium sulfate was found to be superior to placebo with a pain-free rate of
87% for magnesium sulfate compared to 0% for placebo [47].
Frank et al. published a randomized double-blind placebo-controlled trial comparing 2 g of IV
magnesium versus placebo for the treatment of 42 patients (21 in each treatment group) with
acute benign headache who presented to the EDs of two teaching hospitals. Authors found no
benefit of IV magnesium compared to placebo [48].
A meta-analysis of trials including 295 patients treated with intravenous magnesium for acute
migraine failed to demonstrate a beneficial effect in terms of reduction in pain and decrease for
rescue medication. It also showed that patients treated with magnesium were significantly more
likely to report adverse events [49].
In one study metoclopramide was more effective than magnesium with statistically significant
differences [50]. In another study comparing a neuroleptic agent (prochlorperazine) and
magnesium, the results were not statistically significant [51]. A small case series reviewed the
effect of intravenous magnesium therapy for 20 adolescent patients (range 13–18 years old): 5
with migraine, 4 tension-type headache, and 11 with status migrainosus. Although the treatment
showed good tolerability there was no clear efficacy, although the study was limited by small
sample size, multiple potential confounders, and lack of controls. There are no available
controlled studies in the pediatric population.
6.

Diphenhydramine. The role of histamine in the pathophysiology of migraine is still under

investigation but studies suggest benefits from intravenous administration. A study by
Somerville [52] reported that the administration of an acetaminophen-codeine combination plus
the antihistamine doxylamine significantly relieved acute migraine attacks compared with

placebo. Swidan and colleagues compared the efficacy of intravenous diphenhydramine with
dihydroergotamine mesylate (DHE) in the treatment of severe, refractory, migraine headache in
eighty patients divided into two groups of 40 patients each. Comparison was made between nine
doses of diphenhydramine (25 to 75 mg administered intravenously three times daily) and nine
doses of DHE (0.25 to 1.0 mg administered intravenously approximately every 8 hours) during a
3-day period. Patients receiving DHE also received 10 to 15 mg of metoclopramide administered
orally or intravenously approximately 30 minutes before the DHE for nausea prophylaxis.
Intravenous diphenhydramine was noted to reduce pain levels more effectively than DHE
immediately after its administration although overall DHE was associated with greater reduction
in head pain level after the full nine doses (pre- and post protocol pain scores were compared).
Despite the study’s limitations authors concluded that diphenhydramine could be effective in the
treatment of some patients with intractable chronic migraine [53].
7.

Antiemetics. The majority of available data available mostly focus on outcome of

treatment in the emergency department or infusion settings. According to a systematic review
from the Canadian Headache Society, intravenous prochlorperazine is strongly recommended at
a dose of 10 mg as high quality evidence for acute ttreatment of migraine [54]. Multiple clinical
trials have showed superior effect compared to placebo, SC sumatriptan and sodium valproate
[54-57]. Intravenous droperidol [58,59] is effective in status migranosus and more effective than
placebo in controlled trials for acute migraine. Multiple studies also support the use of
chlorpromazine [60,61], haloperidol [62], and metoclopramide [63,64] with or in conjunction
with DHE treatment. EKG monitoring is recommended for drugs which may prolong QT
interval.

8.

Propofol. Intravenous propofol in both subanesthetic and sedating doses has been

reported to be effective for acute migraine in outpatient [65] and emergency department settings
[66,67]. In a small study conducted in an inpatient setting for airway monitoring, 18 patients
with chronic daily headache (14 with chronic migraine) were treated with repetitive boluses of
propofol with a mean total dose of 234mg [68]. Six achieved headache freedom and 11 reported
reduced headache intensity with a mean decrease of 4.2 points on a 10 point scale. There were no
adverse events other than drowsiness, and in fact patients who slept between boluses had more
pain relief.
Inpatient migraine treatment in children:
Children account for about 1/3 of ED visits and the prevalence of headache as a chief complaint
in pediatric EDs is similar to adults [69]. In children presenting with headache as a chief
complaint in the ED, migraine is the second most common etiology following viral upper
respiratory tract infection [70]. Although a careful history is essential, serious secondary
headaches in children usually present with clear neurological abnormalities on exam [71]. A
substantial minority of children with migraine fails to improve with emergency treatment and
may be candidates for inpatient management [72]. Given that migraine causes severe disability
and that children are expected to attend school regularly, untreated migraine in children may
have profound implications. The treatment of children with migraine and other headache is
largely drawn from protocols used in adults. Many treatments used for adults with headache have
not been adequately studied in children, such as the use of corticosteroids. There have been a few
significant pediatric studies of inpatient headache treatment, and other adult studies which have
included adolescents.

A recent survey of headache specialists asked respondents to list their preferred treatments based
on a clinical case of a 14 year-old girl with uncomplicated migraine [22]. Preferred treatments
included, in order, NSAIDs, dopamine antagonists, hydration, IV magnesium, and triptans.
Respondents selected DHE, corticosteroids and valproic acid more often as second line
treatments. Opioids and barbiturate-containing medications were not recommended.
Linder reported the successful inpatient use of combined metoclopramide and dihydroergotamine
for children aged 6 and older. Patients who had previously failed outpatient treatment received
oral metoclopramide followed by intravenous DHE. Linder selected oral metoclopramide after
observing side effects such as sedation, akathisia and extrapyramidal effects with intravenous
prochlorperazine, metoclopramide, and promethazine. The protocol for inpatient included
metoclopramide 0.2 mg/kg 30 minutes prior to DHE doses adjusted for age (0.1 mg age 6-9, 0.15
mg age 9-12, 0.2 mg age 12-16) every 6 hours, with the ability to increase dose by 0.05 mg each
time if tolerated up to a maximum of 0.5 mg/dose. Of 30 children, 24 reported an excellent
response (90% improvement of either headache frequency or intensity or 75% improvement of
both) [28].
Kabbouche reported the use of prochlorperazine 0.13-15 mg/kg with migraine using a higher
dose of DHE 0.5-1 mg every 8 hours in pediatric inpatients with migraine [72,73]. To prevent
the development of extrapyramidal effects, prochlorperazine was changed to another neuroleptic
after 3 doses. After 10 doses, 97% of children reported improvement and 77% headache
freedom.
Nagy et al. [32] reported the inpatient use of DHE in patients with multiple headache disorders
such as migraine, cluster headache and new daily persistent headache over 5 days including

children. In their pediatric patients under 16 they dosed DHE by weight in kilograms, using
intravenous ondansetron 4 mg 30 minutes prior to DHE and giving an extra 4 mg or an
alternative antinausea medication such as promethazine for those with significant nausea.
Although they did not report pediatric outcomes separately, patients with migraine, cluster
headache and NPDH with migraine features often improved both during the treatment with
continued improvement after discharge.
Raina [74] reported a case series describing the use of DHE for the treatment of 6 children, 5 of
them female, aged 13-19 with likely abdominal migraine. Patients initially received 0.5 mg and a
total of 7-11 mg during their hospitalizations. Nausea was a very common side effect.
Lake et al [75] reported a prospective outcome study in inpatients with headache with an age
range of 13-73. After an structured inpatient program consisting of intravenous
dihydroergotamine mesylate or hydrocortisone over 3 days, combined with clinical
psychological evaluation and follow-up, over 60% of patients reported at least 50% improvement
in severe headache days with lower rates of acute medication use, and improved sleep and
functional performance. Pediatric outcomes were included in the overall outcomes.
Two case series including adolescents have [42,43] reported the inpatient use of intravenous
lidocaine for the treatment of chronic daily headache with most of those having chronic
migraine. Williams and Stark reviewed outcomes in those aged 16-74 over a period of 3-17 days
while Rosen et al. studied those aged 17-66 years old over a period of 2-15 days. Patients
received a dose of 2 mg/minute if tolerated. Further increases were based on tolerability, serum
lidocaine levels and headache improvement. Although the majority of patients in both series

reported complete or partial improvement, even those with medication overuse, pediatric
outcomes were not reported separately.
Lanzi and colleagues [76] reported an open-label comparison of inpatient admission compared
with outpatient care for children with at least 2 months of moderate-severe migraine or tensiontype headache. During hospitalizations, children and their families received psychological care
including 3 individual interviews focusing on fears, family and social relationships and
behavioral problems. In addition a child and adolescent psychiatrist assessed hospitalized child
for co-morbid conditions. Neither group of children received prophylactic treatment for
migraine. At 1, 3 and 6 months, those children who were hospitalized had significantly fewer
attacks, less severe attacks and less medication use compared to those who had outpatient care.
Heschler et al. [77] reported outcomes from a 3-week multimodal inpatient pain program for
children and adolescents with chronic pain, with headache being the most common complaint
among these subjects (84/167, 50%) followed by recurrent abdominal pain (22/167, 13%). At
baseline, 42% of patients reported severe pain and 55% very severe pain. A multiprofessional
team including pediatricians, clinical psychologists, children and adolescent psychiatrists,
pediatric nurses, physiotherapists, occupational therapists,and social workers evaluated these
children and initiated treatment which included psychotherapy, cognitive-behavioral therapy,
development of pain-coping strategies, family therapy, music and art therapy. After 3 month
follow-up, treated children made significant improvements in pain intensity, school absence and
acute medication use.
Conclusion:

The effective inpatient treatment of migraine involves both acute medication to reduce pain and
preventive treatments to improve long-term outcomes. The general principles of inpatient
management are listed in Table 1. The majority of persons admitted for migraine are admitted on
an emergency basis for short periods of time to address relatively acute problems. However,
based on the above studies involving large tertiary headache centers, most of the protocols for
intractable migraine require a much longer length of stay. Prior to admission it is important to
address the goals and priorities of admission. This should include issues such as school or work
disability, family and plans for after discharge. For patients with medication-overuse, especially
those using opioids or barbiturates, decreasing their daily dose prior to admission will allow a
more successful treatment, as detoxification from very high doses may not be possible during a
relatively brief hospitalization. An inpatient hospitalization offers the opportunity to strengthen
therapeutic relationships with patients, observe family dynamics and relationships, and provide
education about migraine and chronic pain. Diagnostic testing, when indicated, can rule out
important secondary causes of headache. Given that many patients with secondary headache
such as idiopathic intracranial hypertension [78] have features of migraine, lumbar puncture may
be necessary.
The medications used to treat migraine in the inpatient setting are somewhat different than those
recommended in the outpatient setting as established by clinical trials [79]. Most migraine
clinical trials focus on acute migraine and exclude those with chronic migraine and medicationoveruse. Short-acting medications such as triptans and opioids should not typically be used for
inpatient migraine, especially in those with intractable disease or medication-overuse as an
outpatient. Inpatient treatment of migraine often involves medications which require special
monitoring: DHE may increase blood pressure and monitoring blood pressure is recommended;

many neuroleptics are associated with prolonged QT interval requiring frequent
electrocardiograms; prolonged use of intravenous lidocaine may require telemetry monitoring or
drug levels. A knowledgeable nursing staff familiar with migraine, common adverse events and
the administration of these medications is very helpful.
The use of ancillary services is important for the management of intractable headache disorders.
Multiple affective disorders are strongly linked with chronic migraine, including depression,
anxiety and bipolar spectrum disorders [80]. Abuse and maltreatment, especially early in life, are
strongly linked with migraine chronification [81]. Given that several studies have described the
effectiveness of mental health treatment in improving long-term outcomes in pain disorders, a
psychologist with interest in pain disorders should be part of the migraine treatment team.
Physical therapy may also be useful as neck pain and muscle spasm are extremely common in
persons with migraine. Given the strong association with obesity and migraine chronification
[82], nutrition consultant may improve long-term outcomes, especially given recent evidence
that long-term weight loss appears to improve migraine severity [83].
Patients receiving inpatient treatment for migraine will continue to require close follow-up after
discharge. Almost all will need at least one preventive medication treatment, and may need to
continue titrating medications started during or before the hospitalization. Because most
preventives work best over time, it is important to ensure that patients continue their preventive
medications after discharge. At the time of discharge, a written plan should explain how to treat
migraine with acute medications when they do occur using the principles of stratified care [84].
Often response to treatment in the hospital will guide acute care after discharge. In most patients,
this will mean not taking medication for mild headaches and using an NSAID, antiemetics, DHE

or triptans at migraine onset. Neuroleptics and other sedating medications may be considered as
a rescue treatment. Opioids and corticosteroids should generally be avoided for regular use but
may be considered for special situations in which other medications are contraindicated. A nonoral option may worthwhile, especially in patients who either overuse oral medications or with
frequent nausea or vomiting. Discharging providers should provide referrals to appropriate
providers such as psychologists, psychiatrists, physical therapy or nutrition at the time of
discharge. If possible having a follow-up appointment before discharge scheduled no more than a
few weeks later is ideal.
Table 1: Principles for inpatient migraine treatment
Carefully titrate medications to effective doses

Withdraw opioids and barbiturates if possible

Use long-acting medications to break cycle of

Monitor EKG, blood pressure, and consider

daily headache such as DHE

telemetry depending on drugs used

Address medication-overuse if present

Titrate preventive medication

Utilize mental health providers to assist with

Provide a clear discharge plan for acute

pain-coping strategies

migraine after discharge
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